Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease

Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer’s disease

Abstract A growing literature suggests that plasma levels of tau phosphorylated at amino acid 217 (pTau217) performs similarly to cerebrospinal fluid (CSF) biomarkers and PET imaging to detect amyloid pathology and to provide diagnostic and prognostic information in Alzheimer’s disease (AD), but a s...

Full description

Bibliographic Details
Main Authors: Pia Kivisäkk, Hadia A. Fatima, Danielle S. Cahoon, Brunah Otieno, Leena Chacko, Farnaz Minooei, Catherine Demos, Martin Stengelin, George Sigal, Jacob Wohlstadter, Steven E. Arnold
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-51334-x

Internet

https://doi.org/10.1038/s41598-024-51334-x

Similar Items